Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 4,724 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Signs and Symptoms, Respiratory Clear all

Conditions: Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
Interventions: LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxel; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 17
States / cities: Santa Monica, California • Aurora, Colorado • Denver, Colorado + 10 more

Conditions: Spinal Cord Injuries, Spinal Cord Diseases, Paralysis, Central Nervous System Diseases, Cough
Interventions: Spinal Cord Stimulation, Expiratory Muscle Stimulator; Procedure · Device
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Heart Failure, Crackles, Heart Failure With Preserved Ejection Fraction
Interventions: Use of Eko CORE and Eko DUO electronic stethoscopes; Device
Lead sponsor: Eko Devices, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Timeline: 2020
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hyperoxia
Interventions: ORi sensor; Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Placebo, TrIP-2D, TrIP-2SS, TrIP-2SS + Foradil; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: QAX576, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 7
States / cities: Gainesville, Florida • Orlando, Florida • Boston, Massachusetts + 4 more

Conditions: Cough, Idiopathic Pulmonary Fibrosis
Interventions: Orvepitant Maleate, Placebo; Drug
Lead sponsor: Nerre Therapeutics Ltd.; Industry
Eligibility: 40 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 13 more

Conditions: COPD
Interventions: Loop Band; Device
Lead sponsor: Spry Health; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Pasadena, California

Conditions: COVID Long-Haul, COVID-19, COVID-19 Pandemic, Brain Fog, Memory Deficits, Concentration Ability Impaired, Fatigue
Interventions: cross-sectional MRI and EEG assessments (NO INTERVENTION); Other
Lead sponsor: San Francisco Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pulmonary Disease, Chronic Obstructive, Heart Failure
Interventions: Pharmacist Counseling; Procedure
Lead sponsor: Wilkes University; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Scranton, Pennsylvania

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT001 MDI, Ipratropium Bromide HFA Inhalation Aerosol, Placebo MDI; Drug · Other
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 8
States / cities: Panama City, Florida • Winter Park, Florida • Cherry Hill, New Jersey + 5 more

Conditions: Non-Cystic Fibrosis Bronchiectasis
Interventions: Ciprofloxacin for Inhalation, Placebo; Drug
Lead sponsor: Aradigm Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 11 more

Conditions: Advanced Solid Tumors
Interventions: OSI-906; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Proactive Outreach, No Proactive Outreach; Other
Lead sponsor: Harvard Medical School (HMS and HSDM); Other
Eligibility: Not listed
Enrollment: 19,113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Chicago, Illinois • Louisville, Kentucky • Boston, Massachusetts

Conditions: Epistaxis
Interventions: Tranexamic Acid, Placebo; Drug · Other
Lead sponsor: Mercy Health Ohio; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Boardman, Ohio • Youngstown, Ohio

Conditions: Antimicrobial Stewardship, Acute Bronchitis, Upper Respiratory Infection
Interventions: Antibiotic Stewardship; Behavioral
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Asthma
Interventions: Indacaterol 27.5 mcg, Indacaterol 37.5, Indacaterol 55 mcg, Indacaterol 75 mcg, Indacaterol 150 mcg, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 12
States / cities: Huntington Beach, California • Los Angeles, California • Mission Viejo, California + 9 more

Conditions: Interstitial Lung Disease
Interventions: Amitriptyline 25 MG, Amitriptyline 50 MG, Duloxetine 30 MG, Duloxetine 60 MG, Placebo 30 MG, Placebo 60 MG; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Dyspnea, Acute Heart Failure, Shortness of Breath
Interventions: Treatment as per model probability, Treatment as per usual care; Other
Lead sponsor: Unity Health Toronto; Other
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Myopathy, Cognitive Impairment
Interventions: Biopsy/Ultrasound; Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: Not listed
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Inflammation, COVID19
Interventions: palmitoylethanolamide, Placebo, Curcumin, Control (microcrystalline cellulose); Dietary Supplement
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: COVID-19
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 19 Years to 74 Years
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Calfactant, Room Air (placebo); Drug
Lead sponsor: Pneuma Pharmaceuticals Incorporated; Other
Eligibility: 12 Years to 85 Years
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 18
States / cities: Gainesville, Florida • Orlando, Florida • Chicago, Illinois + 14 more

Search by objective public record fields.

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Sub-study to Spinal Cord Stimulation to Restore Cough

Heart Failure Monitoring With Eko Electronic Stethoscopes

Correlation of Changes in PaO2 and ORi in Adult Patients

ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD

Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis

Loop Band Validation Study

Neural and Cognitive Consequences of COVID-19 Survival

Improving Medication Adherence Through a Transitional Care Pharmacy Practice Model

PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Safety and Efficacy Study of Ciprofloxacin for Inhalation in Patients With Non-Cystic Fibrosis Bronchiectasis "ORBIT-1"

Study of Continuous OSI-906 Dosing

Racial Inequality in Inhaler Fills for COPD - A Trial of Reduced Cost-Sharing

Intranasal TXA for Anterior Epistaxis in the Emergency Department

Using Behavioral Science to Reduce Inappropriate Antibiotic Use in Acute Care Settings

Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma

Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough

Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department

Critical Illness Myopathy as a Cause of Debilitating ICU-Acquired Weakness

Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency

Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19

Mechanisms Underlying Cardiovascular Consequences Associated With COVID-19 and Long COVID

Calfactant for Direct Acute Respiratory Distress Syndrome